Study Says FDA Reviews New Drugs Faster Than EU, Canada

Law360, New York (May 16, 2012, 8:46 PM EDT) -- The U.S. Food and Drug Administration has significantly outpaced its European and Canadian counterparts over the past decade when it comes to reviewing new drugs, according to a study published Wednesday in the New England Journal of Medicine.

Researchers looked at novel therapies approved from 2001 through 2010 by either the FDA, the European Medicines Agency or Health Canada, analyzing about 500 drugs overall, nearly 15 percent of which were greenlighted by all three agencies.

Median review time at the FDA was 322 days, compared with...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.